1031639-13-0Relevant articles and documents
Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors
Azeredo, Luís Felipe S.P.,Coutinho, Julia P.,Jabor, Valquiria A.P.,Feliciano, Patricia R.,Nonato, Maria Cristina,Kaiser, Carlos R.,Menezes, Carla Maria S.,Hammes, Amanda S.O.,Caffarena, Ernesto Raul,Hoelz, Lucas V.B.,de Souza, Nicolli B.,Pereira, Glaécia A.N.,Cerávolo, Isabela P.,Krettli, Antoniana U.,Boechat, Nubia
, p. 72 - 83 (2017)
Malaria remains one of the most serious global infectious diseases. An important target for antimalarial chemotherapy is the enzyme dihydroorotate dehydrogenase from Plasmodium falciparum (PfDHODH), which is responsible for the conversion of dihydroorotat
Cyclocondensation of N-aryl-3-oxobutanethioamides with 5-amino-3-R-4-R 1-pyrazoles
Britsun
experimental part, p. 1262 - 1266 (2009/05/27)
The cyclocondensation products of N-aryl-3-oxobutanethioamides with 5-amino-3-R-4-R1-pyrazoles are 4-(arylamino)-2-methyl-7-R-8-R 1-pyrazolo[1,5-a]pyrimidine and pyrazolo[1,5-a]pyrimidine-4-thione derivatives, the ratio of which depends on the nucleophilicity of the starting 5-amino-3-R-4-R1-pyrazoles and the presence of a proton donor solvent.